Integra LifeSciences Holdings Corp.
Integra LifeSciences Launches Integra® SurgiMend(TM) PRS Meshed Collagen Matrix for Breast Reconstruction in Europe
Expands SurgiMend(TM) technology breast reconstruction product line
PLAINSBORO, N.J., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its acellular dermal tissue matrix (ADM) product line for plastic and reconstructive surgery, including breast reconstruction in Europe, with the introduction of Integra® SurgiMend(TM) PRS Meshed.
Integra SurgiMend PRS Meshed has received CE Mark approval and expects to begin a full market release in Europe in October 2017. Integra's newest acellular dermal matrix (ADM) product was presented at the London Breast Meeting on September 7 - 9, 2017 and was extremely well-received by the surgeon delegates.
Integra SurgiMend PRS, an acellular dermal tissue matrix derived from bovine dermis, is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. It is specifically indicated for plastic and reconstructive surgery, including breast reconstruction. The SurgiMend PRS Meshed solution offers patients the possibility for one single-stage implant breast reconstruction post-mastectomy, instead of multiple-stage surgery.
"We believe that our product offers a real potential to reduce operating time and post-operative pain and morbidity, whilst maintaining aesthetic & functional outcomes, which are key benefits to the patient," says Lesley Whitlock, director of New Business Development, Integra Europe.
"We are proud to launch the first meshed ADM, specifically intended for breast reconstruction. It will increase the surgeon's choice for both pre- and sub-pectoral breast reconstruction using the trusted SurgiMend technology, while meeting the patient demand for one-stage pre-pectoral breast reconstruction in Europe," said Stéphane Corp, vice president, Tissue Technologies, Integra Europe.
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com .
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company
+ 1 609 750 2827
Laurene Isip (U.S.)
+ 1 609 750 7984
Marie-Anne Girel (Europe)
+ 33 4 37 47 59 70
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Barings17.10.2017 16:31 | pressemeddelelse
Barings Supports New Mountain Capital Investment in DRB Systems
Crown Bioscience Inc.17.10.2017 16:14 | pressemeddelelse
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds
Oxford Immunotec17.10.2017 15:17 | pressemeddelelse
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
IASLC17.10.2017 08:17 | pressemeddelelse
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions
EPAM Systems, Inc17.10.2017 06:03 | pressemeddelelse
New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris
LogicBio Therapeutics, Inc.16.10.2017 15:01 | pressemeddelelse
LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum